| Indicators | Browse All

Virax Biolabs Group Limited (VRAX)

Healthcare | Biotechnology | Lanarkshire, United Kingdom | NasdaqCM
4.07 USD -0.01 (-0.245%) ⇩ (July 13, 2026, 4 p.m. EDT)

Short-term:★☆☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 5:39 a.m. EDT

The immediate outlook is severely clouded by a brutal multi-year price collapse and deteriorating fundamentals. While recent headlines celebrate a commercial supply agreement and a 100% intraday spike, the underlying reality is stark: the stock has lost 99.5% of its value over the last three years, with every single year showing negative returns. This is not a temporary dip; it is a structural implosion where the market has repeatedly rejected the business model. Fundamentally, the company is hemorrhaging cash with operating margins of -352%, negative free cash flow, and a forward P/E that implies no earnings. The massive gap between the current price and the analyst target of $25 suggests a theoretical recovery, but without positive earnings or a proven path to profitability, this remains a speculative gamble rather than an investment. The recent volatility appears driven by news flow and short-covering rather than a sustainable trend reversal, leaving the near-term trajectory highly uncertain and dangerous.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.285245
AutoARIMA0.456837
AutoTheta0.494973
AutoETS0.506542

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 27%
H-stat 5.23
Ljung-Box p 0.000
Jarque-Bera p 0.184
Excess Kurtosis -0.29
Attribute Value
Sector Healthcare
Debt to Equity Ratio 5.649
Revenue per Share 0.031
Market Cap 3,243,741
Forward P/E -0.68
Beta 1.33
Website https://viraxbiolabs.com

Info Dump

Attribute Value
52 Week Change -0.81287354
Address1 BioCity Glasgow
Address2 Bo’Ness Road Newhouse
All Time High 7,250.0
All Time Low 2.5
Ask 4.64
Ask Size 1
Average Daily Volume10 Day 7,702,340
Average Daily Volume3 Month 2,048,681
Average Volume 2,048,681
Average Volume10Days 7,702,340
Beta 1.331
Bid 3.52
Bid Size 1
Book Value 20.295
City Lanarkshire
Compensation As Of Epoch Date 1,798,675,200
Country United Kingdom
Crypto Tradeable 0
Currency USD
Current Price 4.07
Current Ratio 9.968
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 4.6
Day Low 3.66
Debt To Equity 5.649
Display Name Virax Biolabs
Ebitda -6,048,149
Ebitda Margins 0.0
Enterprise To Ebitda 0.66
Enterprise To Revenue -321.082
Enterprise Value -3,988,801
Eps Current Year -6.0
Eps Forward -6.0
Eps Trailing Twelve Months -12.64
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 4.3884
Fifty Day Average Change -0.3183999
Fifty Day Average Change Percent -0.072554894
Fifty Two Week Change Percent -81.28735
Fifty Two Week High 28.5
Fifty Two Week High Change -24.43
Fifty Two Week High Change Percent -0.857193
Fifty Two Week Low 2.5
Fifty Two Week Low Change 1.5700002
Fifty Two Week Low Change Percent 0.6280001
Fifty Two Week Range 2.5 - 28.5
Financial Currency USD
First Trade Date Milliseconds 1,658,410,200,000
Float Shares 529,035
Forward Eps -6.0
Forward P E -0.67833334
Free Cashflow -3,477,016
Full Exchange Name NasdaqCM
Full Time Employees 26
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.61901003
Gross Profits 7,690
Has Pre Post Market Data 1
Held Percent Insiders 0.02623
Held Percent Institutions 0.04615
Implied Shares Outstanding 796,988
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,022-07-21
Language en-US
Last Fiscal Year End 1,774,915,200
Last Split Date 1,782,432,000
Last Split Factor 1:25
Long Business Summary Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease. It also provides ImmuneSelect, a research-use-only portfolio of peptide pool ELISpot plates and related immune reagents. In addition, the company is involved in research and development activities and the provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, academic institutions, contract research organizations, biopharmaceutical companies, independent laboratories, and distributors. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, United Kingdom.
Long Name Virax Biolabs Group Limited
Market us_market
Market Cap 3,243,741
Market State PRE
Max Age 86,400
Message Board Id finmb_1685878340
Most Recent Quarter 1,774,915,200
Net Income To Common -5,023,750
Next Fiscal Year End 1,806,451,200
Non Diluted Market Cap 3,243,741
Number Of Analyst Opinions 1
Open 3.79
Operating Cashflow -4,621,892
Operating Margins -352.64923
Payout Ratio 0.0
Phone 44 20 7788 7414
Pre Market Change -0.07000017
Pre Market Change Percent -1.7199059
Pre Market Price 4.0
Pre Market Time 1,784,029,674
Previous Close 4.08
Price Eps Current Year -0.67833334
Price Hint 4
Price To Book 0.20054202
Price To Sales Trailing12 Months 261.1077
Profit Margins 0.0
Quick Ratio 9.555
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.00999975
Regular Market Change Percent -0.245092
Regular Market Day High 4.6
Regular Market Day Low 3.66
Regular Market Day Range 3.66 - 4.6
Regular Market Open 3.79
Regular Market Previous Close 4.08
Regular Market Price 4.07
Regular Market Time 1,783,972,800
Regular Market Volume 973,074
Return On Assets -0.54229
Return On Equity -0.78646004
Revenue Growth 6.849
Revenue Per Share 0.031
Sand P52 Week Change 0.20365608
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 796,988
Shares Percent Shares Out 0.0761
Shares Short 60,615
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 42,759
Short Name Virax Biolabs Group Limited
Short Percent Of Float 0.077800006
Short Ratio 0.33
Source Interval 15
Symbol VRAX
Target High Price 25.0
Target Low Price 25.0
Target Mean Price 25.0
Target Median Price 25.0
Total Cash 6,518,205
Total Cash Per Share 11.253
Total Debt 414,387
Total Revenue 12,423
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -12.64
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 7.79435
Two Hundred Day Average Change -3.72435
Two Hundred Day Average Change Percent -0.47782686
Type Disp Equity
Volume 973,074
Website https://viraxbiolabs.com
Zip ML1 5UH